Newly Identified NO‐Sensor Guanylyl Cyclase/Connexin 43 Association Is Involved in Cardiac Electrical Function

Abstract

BackgroundGuanylyl cyclase, a heme‐containing α1β1 heterodimer (GC1), produces cGMP in response to Nitric oxide (NO) stimulation. The NO‐GC1‐cGMP pathway negatively regulates cardiomyocyte contractility and protects against cardiac hypertrophy–related remodeling. We recently reported that the β1 subunit of GC1 is detected at the intercalated disc with connexin 43 (Cx43). Cx43 forms gap junctions (GJs) at the intercalated disc that are responsible for electrical propagation. We sought to determine whether there is a functional association between GC1 and Cx43 and its role in cardiac homeostasis.Methods and Results GC1 and Cx43 immunostaining at the intercalated disc and coimmunoprecipitation from membrane fraction indicate that GC1 and Cx43 are associated. Mice lacking the α subunit of GC1 (GCα1 knockout mice) displayed a significant decrease in GJ function (dye‐spread assay) and Cx43 membrane lateralization. In a cardiac‐hypertrophic model, angiotensin II treatment disrupted the GC1‐Cx43 association and induced significant Cx43 membrane lateralization, which was exacerbated in GCα1 knockout mice. Cx43 lateralization correlated with decreased Cx43‐containing GJs at the intercalated disc, predictors of electrical dysfunction. Accordingly, an ECG revealed that angiotensin II–treated GCα1 knockout mice had impaired ventricular electrical propagation. The phosphorylation level of Cx43 at serine 365, a protein‐kinase A upregulated site involved in trafficking/assembly of GJs, was decreased in these models.Conclusions GC1 modulates ventricular Cx43 location, hence GJ function, and partially protects from electrical dysfunction in an angiotensin II hypertrophy model. Disruption of the NO‐cGMP pathway is associated with cardiac electrical disturbance and abnormal Cx43 phosphorylation. This previously unknown NO/Cx43 signaling could be a protective mechanism against stress‐induced arrhythmia.

Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy

“…Interestingly, the recent inclusion of aldosterone antagonist eplerenone in early DMD cardiomyopathy treatments delayed progressive cardiac dysfunction when compared with standard therapy (89). Eplerenone's direct impact on Cx43 is unknown, but evidence suggests that it may enhance phosphorylation and improve Cx43 function through the nitric oxide (NO) pathway (90), a key mediator of Cx43 localization in hypertrophic hearts (91).…”

cGMP Signaling in the Neurovascular Unit—Implications for Retinal Ganglion Cell Survival in Glaucoma

“…Rat mesangial cells treated with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) or 8-Br-cGMP increased expression of Cx43 [ 101 ]. Additionally, GC1 −/− mice exhibit Cx43 phosphorylation in the intercalated disc of cardiac tissue, resulting in dysfunctional gap junction electrical conductivity [ 102 ]. Finally, in rodent vascular smooth muscular cells, Cx43 expression increases in response to either 8-Br-cGMP treatment or BAY 41-2272, a GC1 stimulator, and PKG inhibition reverses this increase [ 103 ].…”

Calcium and Heart Failure: How Did We Get Here and Where Are We Going?

“…Potent drugs are now available to augment these signaling systems with conventional soluble guanylate cyclase (sGC) stimulators, novel NO-independent sGC stimulators, GC-A and GC-B agonists, and PDE inhibitors [ 182 , 184 , 185 , 186 ]. Guanylate cyclase has recently become a new target for the treatment of heart failure [ 187 , 188 ]. In clinical trials, the incidence of death from heart failure has been reported to be lower for patients receiving vericiguat, a guanylate cyclase stimulator [ 188 ].…”